StreetInsider.com News Articles

Form 4 Enliven Therapeutics, For: Aug 17 Filed by: Hohl Benjamin

Wed, 19 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260819/26950309.html

Form 4 Enliven Therapeutics, For: Aug 17 Filed by: Hohl Benjamin

Wed, 19 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260819/26950309.html

Form 4 Enliven Therapeutics, For: Aug 17 Filed by: Collins Helen Louise

Wed, 19 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260819/26950280.html

Form 4 Enliven Therapeutics, For: Aug 17 Filed by: Collins Helen Louise

Wed, 19 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260819/26950280.html

Enliven Therapeutics (ELVN) PT Raised to $73 at Mizuho

Tue, 18 Aug 2026 06:36:18 -0400

Mizuho analyst Salim Syed raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $73.00 (from $62.00) while maintaining a Outperform rating.

William Blair Starts Enliven Therapeutics (ELVN) at Outperform

Tue, 18 Aug 2026 06:02:00 -0400

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Outperform rating.

The analyst comments "The continually expanding chronic myeloid leukemia market requires treatment options with improved benefit-risk balance. Prevalence of chronic myeloid leukemia (CML) has increased roughly 35-fold over the past 30 years and is expected to approach up to 10 million cases worldwide between 2040 and 2050. Despite multiple approved tyrosine kinase inhibitors (TKIs) for CML on the market, unmet need remains as a growing pool of late-line patients seek more effective, tolerable, and convenient treatment options. We estimate the current total addressable market for

William Blair Starts Enliven Therapeutics (ELVN) at Outperform

Tue, 18 Aug 2026 06:02:00 -0400

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Outperform rating.

Barclays Starts Enliven Therapeutics (ELVN) at Overweight

Tue, 18 Aug 2026 06:00:58 -0400

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Overweight rating and a price target of $78.00.

The analyst comments "We initiate coverage of Enliven Therapeutics (ELVN) at Overweight with a $78 price target. Enliven Therapeutics is a clinical stage biotechnology company focused on the development of small molecule therapeutics to treat cancers. Lead asset ELVN-001 is a BCR-ABL active site inhibitor that has demonstrated differentiated efficacy from previous generation active site inhibitors in patients with chronic myeloid leukemia (CML), including in patients previously treated with NVS's allosteric inhibitor Scemblix (asciminib). ELVN is moving to initiate a

Barclays Starts Enliven Therapeutics (ELVN) at Overweight

Tue, 18 Aug 2026 06:00:58 -0400

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Overweight rating and a price target of $78.00.

Form 4 Enliven Therapeutics, For: Aug 04 Filed by: Derynck Mika K

Thu, 06 Aug 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260806/26886059.html

Form 4 Enliven Therapeutics, For: Aug 04 Filed by: Derynck Mika K

Thu, 06 Aug 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260806/26886059.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: FMR LLC

Thu, 06 Aug 2026 10:21:00 -0400

si-local-file:///var/storage/secattach/20260806/26881108.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: FMR LLC

Thu, 06 Aug 2026 10:21:00 -0400

si-local-file:///var/storage/secattach/20260806/26881108.html

Enliven Therapeutics (ELVN) PT Raised to $75 at Baird

Thu, 06 Aug 2026 08:29:54 -0400

Baird analyst Colleen Kusy raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $75.00 (from $60.00) while maintaining a Outperform rating.

Enliven Therapeutics (ELVN) PT Raised to $82 at Stifel

Thu, 06 Aug 2026 08:09:21 -0400

Stifel analyst Dara Azar raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $82.00 (from $80.00) while maintaining a Buy rating.

Enliven Therapeutics (ELVN) PT Lowered to $78 at Guggenheim

Thu, 06 Aug 2026 07:39:15 -0400

(Updated - August 6, 2026 7:39 AM EDT)

Guggenheim analyst Michael Schmidt lowered the price target on Enliven Therapeutics (NASDAQ: ELVN) to $78.00 (from $80.00) while maintaining a Buy rating.

The analyst commented: "ELVN reported 2Q26 results and provided a development update for ELVN-001, the company's next-generation ATP-competitive BCR-ABL TKI for CML, that was consistent with prior disclosures. Recall, major milestones this quarter included a positive Phase 1b update at EHA from the ongoing ENABLE study of ELVN-001 monotherapy in 2L+ CML, where highlights included numerically improved MMR achieved rate of 40% across evaluable pts, with compelling tolerability remaining a strength (see

Enliven Therapeutics (ELVN) PT Lowered to $78 at Guggenheim

Thu, 06 Aug 2026 07:39:15 -0400

(Updated - August 6, 2026 7:39 AM EDT)

Guggenheim analyst Michael Schmidt lowered the price target on Enliven Therapeutics (NASDAQ: ELVN) to $78.00 (from $80.00) while maintaining a Buy rating.

Enliven Therapeutics (ELVN) PT Raised to $80 at Goldman Sachs

Thu, 06 Aug 2026 06:34:30 -0400

Goldman Sachs analyst Salveen Richter raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $80.00 (from $67.00) while maintaining a Buy rating.

Enliven Therapeutics, Inc (ELVN) Misses Q2 EPS by 49c

Wed, 05 Aug 2026 18:17:40 -0400

Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q2 EPS of ($0.49).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.

Form 10-Q Enliven Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26874572.html

Form 10-Q Enliven Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26874572.html

Form 8-K Enliven Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26874270.html

Form 8-K Enliven Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26874270.html

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Wed, 05 Aug 2026 16:05:00 -0400

Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile

Reached alignment with the FDA on key Phase 3 trial design components

Strong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030

BURLINGAME, Calif., Aug. 5, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Wed, 05 Aug 2026 16:05:00 -0400

Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile

Reached alignment with the FDA on key Phase 3 trial design components

Strong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030